Achieve Life Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHV research report →
Range $12 – $18
Price Chart
About the company
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom.
- CEO
- Andrew D. Goldberg
- IPO
- 1995
- Employees
- 28
- HQ
- Bothell, WA, US
Get TickerSpark's AI analysis on ACHV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $697.68M
- P/E
- -4.03
- Fwd P/E
- 64.92
- PEG
- 0.23
- P/S
- 0.00
- P/B
- 3.24
- EV/EBITDA
- -4.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -225.39%
- ROIC
- -32.97%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-228,000+0.4%
- Op Income
- $-54,880,000
- Net Income
- $-54,648,000-37.2%
- EPS
- $-1.25-0.8%
- OCF Growth
- -66.2%
- FCF Growth
- -66.2%
- 52W High
- $8.64
- 52W Low
- $2.62
- 50D MA
- $6.99
- 200D MA
- $5.78
- Beta
- 2.41
- RSI (14)
- 38
- Avg Volume
- 1.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Achieve said it ended Q1 with a stronger capital base, a new U.S.-based manufacturing plan, and a more experienced commercial team as it prepares for an NDA resubmission in Q4 2026 and a potential first-half 2027 launch.· May 12, 2026
- Closed a transformational private placement with $180 million upfront and up to $174 million more via milestone-based warrants.
- Management now expects to resubmit the NDA in Q4 2026 and still targets a commercial launch in the first half of 2027.
- Achieve is shifting manufacturing to Adare Pharma Solutions in the U.S.; it said it produced its first cytisinicline engineering batch there in Q1.
- The company is planning to commercialize independently with its own field force and added executives with launch experience from Verona Pharma.
- New clinical data continue to support cytisinicline, including 32.4% continuous abstinence vs. 6% on placebo in a hard-to-treat subgroup.
The call did not report revenue, EPS, gross margin, or year-over-year financial metrics. Management said the company completed a private placement that brought in $180 million upfront, with up to $174 million additional from milestone-based warrants exercisable prior to and up to 20 trading days after FDA approval. On operations, Achieve said it produced its first cytisinicline engineering batch at Adare in Q1. Forward-looking guidance remained unchanged: resubmission of the NDA in Q4 2026 and a commercial launch in the first half of 2027; management also said it hopes to initiate the ORCA-V2 vaping study this year.
Andrew Goldberg framed the quarter as a transition point: he said he joined to help move Achieve from late-stage development to commercial execution and emphasized that the company has the capital, asset, and team to do so. He highlighted a strategy centered on independent commercialization, new board and commercial hires, and a U.S.-based supply chain to reduce risk. His tone was confident and mission-driven, repeatedly stressing the public health need for smoking and vaping cessation and the company’s intent to build the right infrastructure to launch at scale.
Mark Oki did not deliver a separate prepared financial review in the transcript, and the call contained no revenue, EPS, or margin discussion. The key financing figure was the $180 million upfront private placement, plus up to $174 million from warrants tied to FDA approval. Management also discussed capital allocation in qualitative terms, saying the company is evaluating every strategy and expenditure, will ramp resources where needed, and now has the resources to support launch preparation, manufacturing transfer, and the vaping program.
Analysts focused on commercial strategy, the NDA resubmission path, manufacturing readiness, and the size/timing of the sales force. Goldberg said Achieve plans to commercialize independently, believes the new team is suited to launch the product itself, and will scale the field force in a disciplined way rather than giving a specific headcount. On the CRL and manufacturing, he said the issue relates to a prior third-party manufacturer’s OAI classification, that Achieve has moved manufacturing to the U.S., and that Adare is the primary supplier going forward. He also said the company expects to initiate ORCA-V2 this year, is not speculating on FDA leadership changes, and views the priority review voucher as evidence the agency recognizes the public health need, though smoking remains the lead indication and does not depend on the voucher.
The company emerged from the quarter with substantial cash from the private placement and claims it can now fund approval and launch execution. Management pointed to encouraging clinical data, including strong abstinence results in prior-treatment-failure patients and 52-week safety/efficacy data expected later this year. The addition of executives who helped lead a major pulmonary launch was presented as evidence that Achieve can build a capable commercial engine.
The biggest risk remains regulatory and manufacturing execution: the company is waiting on the FDA response tied to a prior third-party manufacturer and is pushing resubmission to Q4 2026 because it still needs to complete technology transfer and related steps. The plan for launch and the vaping study still depends on timelines that management described as fluid and subject to agency interaction. Commercially, Achieve is still pre-approval, and management acknowledged it must build awareness and support programs carefully without overcommitting on field force size or launch spend.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.6%
- Shares Outstanding
- 102.90M
- Float Shares
- 74.69M
of shares held by institutions
119 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.61M | ▲ 7.61M |
| Tpg Gp A, LLC | 6.88M | ▲ 6.88M |
| Venbio Partners LLC | 5.91M | ▲ 5.91M |
| Blackrock, Inc. | 5.49M | ▲ 215.26K |
| Logos Global Management LP | 5.42M | ▲ 5.42M |
| Paradigm Biocapital Advisors LP | 4.95M | ▲ 4.95M |
| Propel Bio Management, LLC | 3.86M | ▼ 169.87K |
| Jpmorgan Chase & Co | 3.79M | ▲ 3.76M |
| Marshall Wace, Llp | 3.77M | 0 |
| State Street Corp | 3.72M | ▲ 772.71K |
| Eventide Asset Management, LLC | 3.57M | ▲ 1.35M |
| Vanguard Capital Management LLC | 3.48M | ▼ 660.58K |
Held by 77 ETFs
Biggest fund positions in ACHV by dollar value.
Our ACHV coverage
Recent articles, reports, and earnings notes.
No research on ACHV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACHV report →Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
globenewswire.com · Nov 9
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
globenewswire.com · Nov 2
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
globenewswire.com · Oct 21
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
globenewswire.com · Oct 7
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
globenewswire.com · Oct 6
Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happened
defenseworld.net · Oct 2
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
globenewswire.com · Oct 1
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
globenewswire.com · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.